AI Developments for T and B Cell Receptor Modeling and Therapeutic Design

Artificial intelligence (AI) is accelerating progress in modeling T and B cell receptors by enabling predictive and generative frameworks grounded in sequence data and immune context. This chapter surveys recent advances in the use of protein language models, machine learning, and multimodal integration for immune receptor modeling. We highlight emerging strategies to leverage single-cell and repertoire-scale datasets, and optimize immune receptor candidates for therapeutic design. These developments point toward a new generation of data-efficient, generalizable, and clinically relevant models that better capture the diversity and complexity of adaptive immunity.

💡 Research Summary

The chapter provides a comprehensive review of recent advances in applying artificial intelligence (AI) to the modeling, prediction, and therapeutic design of T‑cell receptors (TCRs) and B‑cell receptors (BCRs). It begins by outlining the biological background of adaptive immune repertoires, emphasizing that V(D)J recombination generates an astronomically large sequence space that can now be sampled at scale through high‑throughput AIRR‑seq technologies. Public repositories such as the Observed Antibody Space (OAS), Observed TCR Space (OTS), VDJdb, ImmuneCODE, and the AIRR Data Commons are catalogued, together with specialized datasets for viral antigens (e.g., CoV‑AbDab, HIV‑NAb panels) and functional measurements (SKEMPI, SAbDab). The authors note that while these resources are invaluable, they suffer from sparse, noisy functional labels and heterogeneous reporting formats (Kd, IC₅₀, ΔΔG, escape fractions), which hampers direct model training and cross‑study comparison.

The review then contrasts early machine‑learning approaches—k‑mer frequencies, motif mining, bag‑of‑words, and shallow classifiers such as SVMs and random forests—with modern deep‑representation learning. Early methods captured local sequence patterns but could not model long‑range dependencies essential for antigen specificity. The advent of transformer‑based protein language models (PLMs) such as ESM‑2, ProtBERT, AntiBERTy, and antibody‑specific models (AbLang, AbMAP) marked a paradigm shift. Trained on hundreds of millions of sequences, these models learn contextual embeddings by predicting masked residues, thereby internalizing structural and functional cues. The chapter details the architecture (self‑attention, feed‑forward layers) and highlights that PLMs dramatically improve downstream tasks such as paratope identification, affinity estimation, clonotype clustering, and repertoire comparison, albeit at high computational cost.

Structural prediction is covered next. Tools like AlphaFold‑Multimer, IgFold, TCRmodel, and TCRdock now routinely generate high‑confidence 3D models of receptors and receptor‑antigen complexes, enabling structure‑guided analyses of binding sites, flexibility, and mutational impacts. The integration of structural data with PLM embeddings further refines predictions of antigen specificity and binding strength.

Generative modeling receives special attention. Diffusion‑based frameworks such as RFdiffusion allow conditional protein design, where user‑specified constraints (target epitope, MHC allele, desired affinity) guide the generation of novel TCR or antibody sequences. The authors discuss strategies for augmenting scarce experimental labels with synthetic ones derived from predictive models, thereby expanding training sets to hundreds of thousands of examples while acknowledging the risk of propagating prediction errors.

Finally, the chapter stresses the importance of unified benchmarks and standardized evaluation pipelines to address label noise (e.g., only ~50 % of VDJdb entries validated) and the diversity of functional readouts. It advocates for a “data‑model‑experiment” triad: robust, standardized datasets; scalable, transferable AI models; and systematic experimental validation. The authors conclude that these integrated, data‑efficient AI approaches are poised to accelerate immuno‑epidemiology insights and the development of next‑generation, clinically relevant immune receptor therapeutics.